论文部分内容阅读
为探讨心钠素基因转移治疗高血压和慢性心肾功能衰竭等慢性疾病的潜力,首先利用逆转录病毒载体获得可表达和分泌人心钠素的遗传工程细胞,然后将这种细胞植于自发性高血压大鼠SHR的皮下。结果发现,人心钠素遗传工程细胞的移植可使动物血浆中的心钠素浓度在移植后第7天时明显升高。在整个实验期间,虽然实验组动物的血压会随个体发育而逐渐升高,但在实验开始后的42d内却始终明显低于空载体组,其中第14天血压的差异高达33mmHg。在实验开始后的第14天和第21天,实验组动物的尿量也明显增加。以上结果说明,人心钠素遗传工程细胞的皮下移植可明显抑制SHR大鼠血压的上升趋势和改善其泌尿功能,提示该方法具有治疗高血压和慢性心肾功能衰竭等慢性疾病的潜力。
In order to explore the potential of atrial natriuretic peptide gene transfer for treatment of chronic diseases such as hypertension and chronic heart failure, genetic engineering cells expressing and secreting human atrial natriuretic peptide were obtained by retroviral vectors. Hypertensive rat SHR subcutaneously. The results showed that human atrial natriuretic factor genetically engineered cells in the animal plasma levels of atrial natriuretic peptide in the 7th day after transplantation significantly increased. Throughout the experiment, blood pressure in experimental animals gradually increased with individual development, but remained significantly lower within 42 days after the start of the experiment compared with the empty carrier group, with a difference of up to 33 mmHg on day 14. On the 14th and 21st days after the start of the experiment, the urine output of the experimental animals also increased significantly. The above results show that the subcutaneous transplantation of human atrial natriuretic peptide genetically engineered cells can significantly inhibit the rising trend of blood pressure and improve urinary function in SHR rats, suggesting that this method has the potential of treating chronic diseases such as hypertension and chronic heart failure and renal failure.